1890114-11-0 Usage
Description
(2S,2'S)-[[(2R, 5R)-1-[3,5-difluoro-4-(4-(4-fluorophenyl)-1-piperidinyl)phenyl]-2,5-pyrrolidinediyl]bis[6-fluoro-2-(2S)-2-pyrrolidinyl 1H-benzimidazole-2,5-diyl)]bis(1-pyrrolidinecarboxylic acid, 1,1'-bis(1,1'-dimethylethyl)ester is a complex organic compound with a specific stereochemistry. It is characterized by its molecular structure, which includes fluorine atoms, pyrrolidine rings, and benzimidazole moieties. (2S,2'S)-[[(2R, 5R)-1-[3,5-difluoro-4-(4-(4fluorophenyl)-1-piperidinyl)phenyl]-2,5-pyrrolidinediyl]bis[6-fluoro-2-(2S)-2-pyrrolidinyl 1H-benzimidzol e-2,5-diyl)]bis(1-pyrrolidinecarboxylic acid, 1,1'-bis(1,1'-dimethylethyl)ester is an intermediate in the synthesis of Pibrentasvir (1353900-92-1), an antiviral agent.
Uses
Used in Pharmaceutical Industry:
(2S,2'S)-[[(2R, 5R)-1-[3,5-difluoro-4-(4-(4-fluorophenyl)-1-piperidinyl)phenyl]-2,5-pyrrolidinediyl]bis[6-fluoro-2-(2S)-2-pyrrolidinyl 1H-benzimidazole-2,5-diyl)]bis(1-pyrrolidinecarboxylic acid, 1,1'-bis(1,1'-dimethylethyl)ester is used as an intermediate in the synthesis of Pibrentasvir (1353900-92-1) for its antiviral properties. Pibrentasvir is an antiviral agent that targets the hepatitis C virus (HCV) and has shown efficacy in treating chronic HCV infection. The compound's unique structure allows it to interfere with the viral replication process, thus providing a therapeutic option for patients suffering from HCV.
Check Digit Verification of cas no
The CAS Registry Mumber 1890114-11-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,8,9,0,1,1 and 4 respectively; the second part has 2 digits, 1 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 1890114-11:
(9*1)+(8*8)+(7*9)+(6*0)+(5*1)+(4*1)+(3*4)+(2*1)+(1*1)=160
160 % 10 = 0
So 1890114-11-0 is a valid CAS Registry Number.
1890114-11-0Relevant articles and documents
PROCESS FOR MANUFACTURING PIBRENTASVIR ACTIVE DRUG SUBSTANCE
-
Paragraph 0118, (2020/03/23)
The present invention relates to compositions of pibrentasvir, drug products thereof, and processes and intermediates for the preparation thereof. This invention relates to the drug product, active drug substance, intermediates, and processes of pibrentasvir, a NS5A inhibitor that is useful in the treatment of hepatitis C.
